Bioassay of prostate-specific antigen (PSA) using microcantilevers

Guanghua Wu, Ram Datar, Karolyn M. Hansen, Thomas Thundat, Richard J Cote, Arun Majumdar

Research output: Contribution to journalArticle

848 Citations (Scopus)

Abstract

Diagnosis and monitoring of complex diseases such as cancer require quantitative detection of multiple proteins. Recent work has shown that when specific biomolecular binding occurs on one surface of a microcantilever beam, intermolecular nanomechanics bend the cantilever, which can be optically detected. Although this label-free technique readily lends itself to formation of microcantilever arrays, what has remained unclear is the technologically critical issue of whether it is sufficiently specific and sensitive to detect disease-related proteins at clinically relevant conditions and concentrations. As an example, we report here that microcantilevers of different geometries have been used to detect two forms of prostate-specific antigen (PSA) over a wide range of concentrations from 0.2 ng/ml to 60 μg/ml in a background of human serum albumin (HSA) and human plasminogen (HP) at 1 mg/ml, making this a clinically relevant diagnostic technique for prostate cancer. Because cantilever motion originates from the free-energy change induced by specific biomolecular binding, this technique may offer a common platform for high-throughput label-free analysis of protein-protein binding, DNA hybridization, and DNA-protein interactions, as well as drug discovery.

Original languageEnglish
Pages (from-to)856-860
Number of pages5
JournalNature Biotechnology
Volume19
Issue number9
DOIs
StatePublished - Sep 15 2001
Externally publishedYes

Fingerprint

Bioassay
Prostate-Specific Antigen
Antigens
Biological Assay
Proteins
Labels
DNA
Nanomechanics
Plasminogen
DNA-Binding Proteins
Drug Discovery
Serum Albumin
Free energy
Prostatic Neoplasms
Throughput
Geometry
Monitoring
Neoplasms

ASJC Scopus subject areas

  • Microbiology

Cite this

Wu, G., Datar, R., Hansen, K. M., Thundat, T., Cote, R. J., & Majumdar, A. (2001). Bioassay of prostate-specific antigen (PSA) using microcantilevers. Nature Biotechnology, 19(9), 856-860. https://doi.org/10.1038/nbt0901-856

Bioassay of prostate-specific antigen (PSA) using microcantilevers. / Wu, Guanghua; Datar, Ram; Hansen, Karolyn M.; Thundat, Thomas; Cote, Richard J; Majumdar, Arun.

In: Nature Biotechnology, Vol. 19, No. 9, 15.09.2001, p. 856-860.

Research output: Contribution to journalArticle

Wu, G, Datar, R, Hansen, KM, Thundat, T, Cote, RJ & Majumdar, A 2001, 'Bioassay of prostate-specific antigen (PSA) using microcantilevers', Nature Biotechnology, vol. 19, no. 9, pp. 856-860. https://doi.org/10.1038/nbt0901-856
Wu, Guanghua ; Datar, Ram ; Hansen, Karolyn M. ; Thundat, Thomas ; Cote, Richard J ; Majumdar, Arun. / Bioassay of prostate-specific antigen (PSA) using microcantilevers. In: Nature Biotechnology. 2001 ; Vol. 19, No. 9. pp. 856-860.
@article{b95b78a4b568449b86e680a526ad3174,
title = "Bioassay of prostate-specific antigen (PSA) using microcantilevers",
abstract = "Diagnosis and monitoring of complex diseases such as cancer require quantitative detection of multiple proteins. Recent work has shown that when specific biomolecular binding occurs on one surface of a microcantilever beam, intermolecular nanomechanics bend the cantilever, which can be optically detected. Although this label-free technique readily lends itself to formation of microcantilever arrays, what has remained unclear is the technologically critical issue of whether it is sufficiently specific and sensitive to detect disease-related proteins at clinically relevant conditions and concentrations. As an example, we report here that microcantilevers of different geometries have been used to detect two forms of prostate-specific antigen (PSA) over a wide range of concentrations from 0.2 ng/ml to 60 μg/ml in a background of human serum albumin (HSA) and human plasminogen (HP) at 1 mg/ml, making this a clinically relevant diagnostic technique for prostate cancer. Because cantilever motion originates from the free-energy change induced by specific biomolecular binding, this technique may offer a common platform for high-throughput label-free analysis of protein-protein binding, DNA hybridization, and DNA-protein interactions, as well as drug discovery.",
author = "Guanghua Wu and Ram Datar and Hansen, {Karolyn M.} and Thomas Thundat and Cote, {Richard J} and Arun Majumdar",
year = "2001",
month = "9",
day = "15",
doi = "10.1038/nbt0901-856",
language = "English",
volume = "19",
pages = "856--860",
journal = "Nature Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Bioassay of prostate-specific antigen (PSA) using microcantilevers

AU - Wu, Guanghua

AU - Datar, Ram

AU - Hansen, Karolyn M.

AU - Thundat, Thomas

AU - Cote, Richard J

AU - Majumdar, Arun

PY - 2001/9/15

Y1 - 2001/9/15

N2 - Diagnosis and monitoring of complex diseases such as cancer require quantitative detection of multiple proteins. Recent work has shown that when specific biomolecular binding occurs on one surface of a microcantilever beam, intermolecular nanomechanics bend the cantilever, which can be optically detected. Although this label-free technique readily lends itself to formation of microcantilever arrays, what has remained unclear is the technologically critical issue of whether it is sufficiently specific and sensitive to detect disease-related proteins at clinically relevant conditions and concentrations. As an example, we report here that microcantilevers of different geometries have been used to detect two forms of prostate-specific antigen (PSA) over a wide range of concentrations from 0.2 ng/ml to 60 μg/ml in a background of human serum albumin (HSA) and human plasminogen (HP) at 1 mg/ml, making this a clinically relevant diagnostic technique for prostate cancer. Because cantilever motion originates from the free-energy change induced by specific biomolecular binding, this technique may offer a common platform for high-throughput label-free analysis of protein-protein binding, DNA hybridization, and DNA-protein interactions, as well as drug discovery.

AB - Diagnosis and monitoring of complex diseases such as cancer require quantitative detection of multiple proteins. Recent work has shown that when specific biomolecular binding occurs on one surface of a microcantilever beam, intermolecular nanomechanics bend the cantilever, which can be optically detected. Although this label-free technique readily lends itself to formation of microcantilever arrays, what has remained unclear is the technologically critical issue of whether it is sufficiently specific and sensitive to detect disease-related proteins at clinically relevant conditions and concentrations. As an example, we report here that microcantilevers of different geometries have been used to detect two forms of prostate-specific antigen (PSA) over a wide range of concentrations from 0.2 ng/ml to 60 μg/ml in a background of human serum albumin (HSA) and human plasminogen (HP) at 1 mg/ml, making this a clinically relevant diagnostic technique for prostate cancer. Because cantilever motion originates from the free-energy change induced by specific biomolecular binding, this technique may offer a common platform for high-throughput label-free analysis of protein-protein binding, DNA hybridization, and DNA-protein interactions, as well as drug discovery.

UR - http://www.scopus.com/inward/record.url?scp=0034874270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034874270&partnerID=8YFLogxK

U2 - 10.1038/nbt0901-856

DO - 10.1038/nbt0901-856

M3 - Article

C2 - 11533645

AN - SCOPUS:0034874270

VL - 19

SP - 856

EP - 860

JO - Nature Biotechnology

JF - Nature Biotechnology

SN - 1087-0156

IS - 9

ER -